The company announced price cuts to Lantus, its most-prescribed insulin product, after similar moves by rivals Novo Nordisk and Eli Lilly and Co.
The Alzheimer’s Association has deployed 1,000 people diagnosed with, or caring for someone with the disease, to meet with all 535 members of Congress across the United States and urge them to press Medicare for early access to a new class of drugs, beginning with lecanemab, that promise to slow the disease.
The U.S. government said it would subject 27 drugs to inflation penalties, a move that will reduce out-of-pocket costs for Medicare recipients by $2 to as much as $390 per average dose.
Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%.
Presently, Medicare is forbidden by law from paying for antiobesity prescriptions. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss.
The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes, and male pattern baldness.
California is suing the United States’ leading insulin makers and pharmacy benefit managers, accusing them of using their market power to overcharge patients for the life-saving drug, the state’s attorney general announced on Thursday.
Billionaire entrepreneur Mark Cuban’s pharmaceuticals startup has tied up with pharmacy benefits manager RxPreferred Benefits, the companies said on Wednesday, in a move to offer lower priced drugs through some employer-backed health insurance plans.